NEW YORK (GenomeWeb News) – Integral Molecular said today that the National Cancer Institute has awarded it a $150,000 contract to map epitopes for monoclonal antibodies directed against cancer biomarkers.

Integral, based in Philadelphia, will analyze protein targets of interest to the clinical cancer proteomics community using shotgun mutagenesis mapping technology to identify amino acids essential for antibody binding and to discover and characterize cancer-specific biomarkers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.